Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)

Srdan Verstovsek, MD PhD, Moshe Talpaz, MD, Ellen K. Ritchie, MD, Martha Wadleigh, MD, Olatoyosi Odenike, MD, Catriona Jamieson, MD PhD, Brady Stein, MD, Candido E. Rivera, MD, Tomonori Uno, PhD, Ruben A. Mesa, MD

Blood (2016) 128 (22): 1936.

https://doi.org/10.1182/blood.V128.22.1936.1936

Published: 2016

Journal Articles

Multicenter Analysis of Clinical Characteristics and Long-Term Outcomes of Transjugular Intrahepatic Portosystemic Shunt Procedure for MPN-Associated Portal Hypertension

Christopher R Reilly, MD, Daria V. Babushok, MD PhD, Karlyn Martin, MD, Jerry L. Spivak, MD, Michael Streiff, MD, Brady Stein, MD, Alison R Moliterno, MD, Elizabeth O. Hexner, MD

Blood (2016) 128 (22): 1943.

https://doi.org/10.1182/blood.V128.22.1943.1943

Published: 2016

Journal Articles

Disease and Clinical Characteristics of Patients with Polycythemia Vera: An Early View of the Reveal Study

Brady Stein, MD, Alison Moliterno, MD, Ralph V. Boccia, MD, Ahmad B. Naim, MD, Joseph A. Cordaro, PharmD,MBA, Wei Peng, PhD, Hao Sun, MS, Shreekant V. Parasuraman, PhD, Ruben A. Mesa

Blood (2015) 126 (23): 2813.

https://doi.org/10.1182/blood.V126.23.2813.2813

Published: 2015

Journal Articles

Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study

Ruben A. Mesa, Ralph V. Boccia, MD, Alison Moliterno, MD, Ahmad B. Naim, MD, Joseph A. Cordaro, PharmD,MBA, Wei Peng, PhD, Hao Sun, MS, Shreekant V. Parasuraman, PhD, Brady Stein, MD

Blood (2015) 126 (23): 4084.

https://doi.org/10.1182/blood.V126.23.4084.4084

Published: 2015

Journal Articles

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

Srdan Verstovsek, MD, Moshe Talpaz, MD, Ellen Ritchie, MD, Martha Wadleigh, MD, Olatoyosi Odenike, MD, Catriona Jamieson, MD PhD, Brady Stein, MD, Tomonori Uno, PhD, Ruben A. Mesa

Blood (2015) 126 (23): 2800.

https://doi.org/10.1182/blood.V126.23.2800.2800

Published: 2015

Journal Articles

Gender Is a Core Modifier of Disease Outcomes and Survival in the MPN

Brady Stein, MD, Jerry L. Spivak, MD, Alison R Moliterno, MD

Blood (2015) 126 (23): 2106.

https://doi.org/10.1182/blood.V126.23.2106.2106

Published: 2015

Journal Articles

Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia

Julie B Waisbren, MD, Shira N. Dinner, MD, Irene Helenowski, PhD, Juehua Gao, MDPhD, Brandon McMahon, MD, Brady Stein, MD

Blood (2015) 126 (23): 3477.

https://doi.org/10.1182/blood.V126.23.3477.3477

Published: 2015

Journal Articles

Burden of Phlebotomy in Patients with Polycythemia Vera in the United States: Baseline Data from the REVEAL Study

Ralph V. Boccia, MD, Brady Stein, MD, Ruben A. Mesa, Ahmad B. Naim, MD, Joseph A. Cordaro, PharmD,MBA, Wei Peng, PhD, Hao Sun, MS, Shreekant V. Parasuraman, PhD, Alison Moliterno, MD

Blood (2015) 126 (23): 5187.

https://doi.org/10.1182/blood.V126.23.5187.5187

Published: 2015

NARROW

Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)

Multicenter Analysis of Clinical Characteristics and Long-Term Outcomes of Transjugular Intrahepatic Portosystemic Shunt Procedure for MPN-Associated Portal Hypertension

Disease and Clinical Characteristics of Patients with Polycythemia Vera: An Early View of the Reveal Study

Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

Gender Is a Core Modifier of Disease Outcomes and Survival in the MPN

Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia

Burden of Phlebotomy in Patients with Polycythemia Vera in the United States: Baseline Data from the REVEAL Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only